DermTech to Present at Upcoming Investor Conferences
February 11 2020 - 5:29PM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced that John Dobak, M.D., Chief
Executive Officer of the Company, is scheduled to present at the
following upcoming investor conferences:
- The 9th Annual SVB Leerink Global Healthcare Conference on
Wednesday, February 26, 2020 at 2:30 p.m. Eastern Time at the Lotte
New York Palace hotel in New York.
- Cowen’s 40th Annual Health Care Conference on Monday, March 2,
2020 at 11:20 a.m. Eastern Time at the Boston Marriott Copley Place
hotel in Boston.
About DermTech:
DermTech is a leader in a new category of medicine, precision
dermatology. DermTech’s mission is to transform the practice of
dermatology through more accurate diagnosis and treatment, and the
elimination of unnecessary surgery, leading to improved patient
care and lower costs. DermTech provides genomic analysis of skin
samples collected non-invasively using an adhesive patch rather
than a scalpel. DermTech markets and develops products that
facilitate the early detection of skin cancers, and is developing
products that assess inflammatory diseases and customize drug
treatments. For additional information on DermTech, please visit
DermTech’s investor relations site at: www.dermtech.com.
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations with respect to the performance, patient
benefits and cost-effectiveness of DermTech’s products. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare and private payors; (5) the ability of patients or
healthcare providers to obtain coverage of or sufficient
reimbursement for DermTech’s products; (6) DermTech’s ability to
grow, manage growth and retain its key employees; (7) changes in
applicable laws or regulations; (8) the market adoption and demand
for DermTech’s products and services together with the possibility
that DermTech may be adversely affected by other economic,
business, and/or competitive factors; and (9) other risks and
uncertainties included in (x) the “Risk Factors” section of the
most recent Quarterly Report on Form 10‑Q filed with the Securities
and Exchange Commission (“SEC”) by the company, and (y) other
documents filed or to be filed with the SEC by the company.
DermTech cautions that the foregoing list of factors is not
exclusive. You should not place undue reliance upon any
forward-looking statements, which speak only as of the date made.
DermTech does not undertake or accept any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement
is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200211006081/en/
Company Contact: Sarah Dion VP Marketing
sdion@dermtech.com (858) 450-4222
Investors: Westwicke, an ICR company Caroline Corner, PhD
caroline.corner@westwicke.com (415) 202-5678
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From Apr 2024 to May 2024
DermTech (NASDAQ:DMTK)
Historical Stock Chart
From May 2023 to May 2024